It seems like very shoddy business practice to base the takeover value of your business on a test you had no idea your product was able to meet or not. It would have been better to say to Pfizer ok but give us a few weeks to tweak the algorithims so it has even a chance in hell to work with the new cases for which it was not designed.
The other thing is on 21 June 2022 RAP stated "The Data Confirmation Study was conducted by ResApp to provide confirmation of the previously announced results of ResApp's pilot study on an independant data set. Given the Data Confirmation Study was ongoing at the time the terms of the Revised Scheme were agreed..." [bold letters mine]. So they seem to be saying they had already started the new study when Pfizer suggested using it to base the price on. This suggests that they did have a chance to tweak the algorithims before they started the new study. Am I on the wrong track here?
It seems like very shoddy business practice to base the takeover...
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
